Survival from common and rare cancers in Germany in the early 21st century

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 472-479

  Hiripi, E ^a   Gondos, A ^a   Emrich, K ^b   Holleczek, B ^c   Katalinic, A ^d   Luttmann, S ^e   Sirri, E ^f   Brenner, H ^a,l   Geiss, Karla ^g   Meyer, Martin ^g   Eberle, Andrea ^g   Luttmann, Sabine ^g   Stabenow, Roland ^g   Hentschel, Stefan ^h   Nennecke, Alice ⁱ   Kieschke, Joachim ⁱ   Sirri, Eunice ^f   Holleczek, Bernd ^c   Emrich, Katharina ^b   Kajüter, Hiltraud ^j   Mattauch, Volkmar ^j   Katalinic, Alexander ^j   Kraywinkel, Klaus ^k   Gondos, Adam ^l   Hiripi, Eva ^l   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Informatics   (Germany)

^c Population based Cancer Registry of the Saarland   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

^f Cancer Registry of Lower Saxony   (Germany)

^g Leibniz Institute for Prevention Research and Epidemiology BIPS   (Germany)

^h Berlin/Brandenburg/Mecklenburg Vorpommern/Sachsen Anhalt/Sachsen/Thuringen   (Germany)

ⁱ Hamburg Cancer Registry   (Germany)

^j Cancer Registry of Schleswig Holstein   (Germany)

^k ROBERT KOCH INSTITUTE   (Germany)

^l Clinical Cooperation Unit Applied Tumor Biology DKFZ   (Germany)

more..

Author keywords

Cancer survival; Germany; Period analysis

Indexed keywords

AGE; ARTICLE; BONE CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; EAR CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EYE CANCER; GALLBLADDER CANCER; GERMANY; HEART CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; KIDNEY PELVIS TUMOR; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MESOTHELIOMA; MOUTH CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NOSE CANCER; OVARY CANCER; PANCREAS CANCER; PARANASAL SINUS CANCER; PENIS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SMALL INTESTINE CANCER; SOFT TISSUE CANCER; STOMACH CANCER; SURVIVAL RATE; TESTIS CANCER; THYROID CANCER; TRACHEA CANCER; UNITED STATES; URETER CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VAGINA CANCER; VULVA CANCER;

EID: 84856321238     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr131     Document Type: Article

References (49)

1. World Health Organisation. Mortality Country Fact Sheet 2006. Germany http://www.who.int/whosis/mort/profiles/mort_euro_deu_germany.pdf (16 February 2011, date last accessed).
2. Gondos A, Arndt V, Holleczek B et al. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer 2007; 121: 395-400.
3. De Angelis R, Francisci S, Baili P et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009; 45: 909-930.
4. Gondos A, Bray F, Hakulinen T, Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564-573.
5. Brenner H, Francisci S, de Angelis R et al. Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 2009; 45: 1028-1041.
6. Capocaccia R, Gatta G, Roazzi P et al. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 2003; 14 (Suppl 5): v14-v27.
7. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
8. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg.). Cancer in Germany 2005/2006. Incidence and Trends. Berlin, Germany: Robert Koch Institute 2010.
9. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and conversion programs for cancer registries. (IARC/IACR tools for cancer registries). Lyon, France: IARC Technical Report No. 42 2005.
10. Henson DE, Ries LA. The relative survival rate. Cancer 1995; 76: 1687-1688.
11. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Bethesda, MD: National Cancer Institute 1959.
12. Brenner H, Hakulinen T. Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 2002; 156: 566-577.
13. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006; 164: 689-696.
14. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-2316.
15. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer 2002; 38: 690-695.
16. Berrino F, Verdecchia A, Lutz JM et al. Comparative cancer survival information in Europe. Eur J Cancer 2009; 45: 901-908.
17. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783.
18. OECD Health Data 2006. How Does Germany Compare? http://www.oecd.org/dataoecd/31/5/36957221.pdf (16 February 2011, date last accessed).
19. Frey CM, McMillen MM, Cowan CD et al. Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 1992; 84: 872-877.
20. Mariotto A, Capocaccia R, Verdecchia A et al. Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control 2002; 13: 101-111.
21. Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 2004; 15: 1027-1034.
22. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006; 17: 5-19.
23. Coleman MP, Rachet B, Woods LM et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 2004 90: 1367-1373.
24. Dejardin O, Remontet L, Bouvier AM et al. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer 2006; 95: 944-949.
25. European Observatory on Health Systems and Policies. Fact Sheet on Germany http://www.euro.who.int/__data/assets/pdf_file/0008/98846/E85472sum.pdf (10 January 2010 date last accessed).
26. OECD Communication. Health Spending in Most OECD Countries Rises, with the U.S. far Outstripping all Others http://www.oecd.org/document/36/0,2340, en_2649_201185_31938380_1_1_1_1,00.html (10 January 2010 date last accessed).
27. Hoffman C, Paradise J. Health insurance and access to health care in the United States. Ann N Y Acad Sci 2008; 1136: 149-160.
28. Hotes JL, Ellison LF, Howe HL et al. Variation in breast cancer counts using SEER and IARC multiple primary coding rules. Cancer Causes Control 2004; 15: 185-191.
29. Breen N, A Cronin K, Meissner HI et al. Reported drop in mammography: is this cause for concern? Cancer 2007; 109: 2405-2409.
30. Malek A, Rabe P et al. Evaluationsbericht 2005-2007 Ergebnisse des Mammographie-Screening Programms in Deutschland. Kooperationsgemeinschaft Mammographie. 2009.
31. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008; 64: 10-19.
32. Becker N. Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 2003; 129: 691-702.
33. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 1414-1420.
34. Stock C, Brenner H. Utilization of lower gastrointestinal endoscopy and fecal occult blood test in 11 European countries: evidence from the Survey of Health, Aging and Retirement in Europe (SHARE). Endoscopy 2010; 42 (7): 545-556.
35. Stock C, Haug U, Brenner H. Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. Gastrointest Endosc 2010; 71: 366-381. e362.
36. Ciccolallo L, Capocaccia R, Coleman MP et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005; 54: 268-273.
37. Brenner H, Arndt V, Stegmaier C et al. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-258.
38. Perez-Perez GI, Rothenbacher D, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2004; 9 (Suppl 1): 1-6.
39. Pinheiro PS, van der Heijden LH, Coebergh JW. Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Lauren type and subsite. Int J Cancer 1999; 84: 28-32.
40. Draube A, Behringer K, Diehl V. German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies. Clin Lymphoma Myeloma 2006; 6: 458-468.
41. Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl 2005; 66: 21-25.
42. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
43. Quaglia A, Tavilla A, Shack L et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009; 45: 1006-1016.
44. Crivellari D, Aapro M, Leonard R et al. Breast cancer in the elderly. J Clin Oncol 2007; 25: 1882-1890.
45. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol 2007; 25: 1891-1897.
46. Janssen-Heijnen ML, Houterman S, Lemmens VE et al. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res 2005; 124: 89-107.
47. Berrino F, Micheli A, Sant M, Capocaccia R. Interpreting survival differences and trends. Tumori 1997; 83: 9-16.
48. Brenner H, Hakulinen T. Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration. Br J Cancer 2005; 92: 576-579.
49. Ries LAG, Young YL, Keel GE et al. Patient and Tumor Characteristics. In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001. Bethesda, MD: National Cancer Institute 2007; SEER Program, NIH Pub. No. 07-6215.